Wczytywanie spółki
Just reported
Q3 2026 results
From Edwards Lifesciences's results release of 4 listopada 2026; its quarterly report has since been filed.
Revenue
Actual
1,72B USD
+10% y/y
-1,5% q/qGuided
1,67B USD
midpoint
Above guide+2,7%EPS, GAAP
Actual
0,53 USD
+6,0% y/y
+26% q/qGuided
—
No guide given
Operating income, GAAP
Actual
299,1M USD
-2,6% y/y
-42% q/qGuided
—
No guide given
Company outlook
Q4 2026
- Revenue1,67B USD – 1,75B USD+8,9% y/y First given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Edwards Lifesciences is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Medical Devices
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plc129,2B USDA+
SYKStryker Corp.118,9B USDA+
GEHCGE Healthcare Technologies Inc.37B USDA
GKOSGlaukos Corp14,6B USDA
PENPenumbra, Inc12,6B USDA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 paź 2026CBGraded C, now B
MCKMckesson Corporation4 lis 2026BAGraded B, now A
CVSCVS Health Corp4 lis 2026BAGraded B, now A
BIIBBiogen Inc.28 paź 2026BAGraded B, now A- GEHCGE Healthcare Technologies Inc.28 paź 2026CAGraded C, now A
Jak zarabia
- Catheter-delivered aortic valve replacement72%
- Catheter-delivered mitral and tricuspid valve repair and replacement11%
- Surgical heart valve products16%
Udziały w przychodach to szacunki za nine months ended September 30, 2026, a nie dane z raportu złożonego do regulatora.
Konkuruje z
Co sprzedaje5
SAPIEN
A family of tissue valves delivered through a catheter to replace a diseased aortic valve; some systems are also used for pulmonary valve replacement.
PASCAL
A catheter-delivered device that helps bring together the leaflets of a leaking mitral or tricuspid valve.
EVOQUE
A tissue valve delivered through a catheter to replace a leaking tricuspid valve.
Pokaż 2 więcej
SAPIEN M3
A tissue valve delivered through a catheter to replace a diseased mitral valve.
INSPIRIS RESILIA, KONECT RESILIA, and MITRIS RESILIA
Surgical tissue valve products for aortic and mitral valve replacement; KONECT is a tissue valve conduit used in complex combined procedures.
Kto to kupuje3
- Hospitals and health systems buy devices directly from Edwards sales teams or through distributors; in the United States, sales are mainly direct.
- Hospital purchasing groups and healthcare networks negotiate supplier contracts on behalf of hospitals.
- Heart specialists, including cardiac surgeons and interventional cardiologists, use the devices and take part in choosing treatments.
Na czym się opiera i co może to zburzyć
Od czego zależy ta działalność
- 1A large part of the business depends on hospitals adopting catheter-delivered aortic valve replacement and on clinicians choosing Edwards devices.
- 2Sales depend in part on government and private insurers covering procedures and paying hospitals enough to support their use.
- 3Some materials and components come from single-source suppliers; switching critical suppliers can require lengthy regulatory review.
- 4The company relies on clinical studies and regulatory clearances or approvals to bring devices to market and expand their permitted uses.
Co może pójść nie tak
- 1If clinical studies do not show the needed results, or regulators do not approve new devices or uses, Edwards may be unable to sell those products or expand their use.
- 2Manufacturing, quality, safety, or delivery problems at Edwards or its suppliers could interrupt access to implanted heart valves and other devices.
- 3If insurers or government health programs restrict coverage or reduce payments, hospitals may buy fewer devices or seek lower prices.
Pełne sprawozdania finansowe →
O spółce Edwards Lifesciences Corporation
Edwards makes devices that replace or repair damaged heart valves. Some are delivered through a catheter, a thin tube passed through a blood vessel, while others are implanted during open-heart surgery. Hospitals and heart specialists use these devices to treat diseases affecting the aortic, mitral, and tricuspid valves.
- Siedziba
- Irvine, California, United States
- Rok założenia
- 1958
- Zatrudnienie
- Approximately 16,000 (December 31, 2025, medium)
- Notowana na
- New York Stock Exchange
- Koniec roku obrotowego
- December 31
Zbudowane z własnych raportów spółki Edwards Lifesciences Corporation składanych do amerykańskiej Komisji Papierów Wartościowych i Giełd (SEC). Liczby są takie, jak zaraportowano, a historia na akcję przeliczona na dzisiejszą bazę akcji. To opisuje firmę — nie jest poradą inwestycyjną ani rekomendacją kupna lub sprzedaży.
